Correction to: Intravenous Ferric Carboxymaltose in Patients with Type 2 Diabetes Mellitus and Iron Deficiency: CLEVER Trial Study Design and Protocol

Diabetes Ther. 2019 Feb;10(1):329-331. doi: 10.1007/s13300-018-0546-6.

¹ Clinical Research Center Hannover and Center for Pharmacology and Toxicology, Hannover Medical School, Hannover, Germany. schindler.christoph@mh-hannover.de.
² Medical Clinic and Policlinic III at the University Hospital Dresden, Dresden, Germany.
³ Centre for Metabolic Vascular Medicine, GWT-TUD, Dresden, Germany.
⁴ Medical Consulting, GWT-TUD, Dresden, Germany.
⁵ Diabetes Center Herne, Herne, Germany.
⁶ Herz- und Diabeteszentrum Nordrhein-Westfalen, Ruhr-Universität Bochum, Bad Oeynhausen, Germany.
⁷ Department of Medicine at the University Hospital Leipzig, Leipzig, Germany.
⁸ Diabetesinstitut Heidelberg and Department of Clinical Studies, St. Josefskrankenhaus Heidelberg, Heidelberg, Germany.

Abstract

In the original publication, the text in Table 2 stated 'Hypersensitivity to the active substance, to Ferinject, or to any of its excipients'.